T Cell Signaling Abnormalities Contribute to Aberrant Immune Cell Function and Autoimmunity

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2015 May 12

PMID 25961450

Citations 120

Authors

Vaishali R Moulton

George C Tsokos

Affiliations

Soon will be listed here.

Abstract

Systemic lupus erythematosus (SLE) is a prototype systemic autoimmune disease that results from a break in immune tolerance to self-antigens, leading to multi-organ destruction. Autoantibody deposition and inflammatory cell infiltration in target organs such as kidneys and brain lead to complications of this disease. Dysregulation of cellular and humoral immune response elements, along with organ-defined molecular aberrations, form the basis of SLE pathogenesis. Aberrant T lymphocyte activation due to signaling abnormalities, linked to defective gene transcription and altered cytokine production, are important contributors to SLE pathophysiology. A better understanding of signaling and gene regulation defects in SLE T cells will lead to the identification of specific novel molecular targets and predictive biomarkers for therapy.

Citing Articles

Deciphering the secret codes in N-methylguanosine modification: Context-dependent function of methyltransferase-like 1 in human diseases.

Fang H, He J, Du D, Wang X, Xu X, Lu L Clin Transl Med. 2025; 15(2):e70240.

PMID: 39979979 PMC: 11842222. DOI: 10.1002/ctm2.70240.

Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases.

Lu Y, Wang Y, Ruan T, Wang Y, Ju L, Zhou M Front Immunol. 2025; 16:1536020.

PMID: 39917294 PMC: 11798928. DOI: 10.3389/fimmu.2025.1536020.

Analysis of expression and its clinical significance of the ADAMTS-2 in systemic lupus erythematosus.

Long D, Zhan J, Tu C, Yu S, Rao J, Luo Q Clin Rheumatol. 2025; 44(2):681-691.

PMID: 39806074 DOI: 10.1007/s10067-025-07303-4.

MicroRNA signatures in neuroplasticity, neuroinflammation and neurotransmission in association with depression.

Choudhary A, Kumar A, Jindal M, Rhuthuparna M, Munshi A J Physiol Biochem. 2024; .

PMID: 39695016 DOI: 10.1007/s13105-024-01065-4.

Autoimmune disease: a view of epigenetics and therapeutic targeting.

Mu S, Wang W, Liu Q, Ke N, Li H, Sun F Front Immunol. 2024; 15:1482728.

PMID: 39606248 PMC: 11599216. DOI: 10.3389/fimmu.2024.1482728.

References

Guo Y, Sawalha A, Lu Q . Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application. Clin Immunol. 2014; 155(1):79-90. DOI: 10.1016/j.clim.2014.09.002. View

Mishra N, Khan I, Tsokos G, Kammer G . Association of deficient type II protein kinase A activity with aberrant nuclear translocation of the RII beta subunit in systemic lupus erythematosus T lymphocytes. J Immunol. 2000; 165(5):2830-40. DOI: 10.4049/jimmunol.165.5.2830. View

Fernandez D, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton F . Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol. 2009; 182(4):2063-73. PMC: 2676112. DOI: 10.4049/jimmunol.0803600. View

Kato H, Perl A . Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol. 2014; 192(9):4134-44. PMC: 3995867. DOI: 10.4049/jimmunol.1301859. View

Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M . Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990; 33(11):1665-73. DOI: 10.1002/art.1780331109. View

Lai Z, Borsuk R, Shadakshari A, Yu J, Dawood M, Garcia R . Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol. 2013; 191(5):2236-46. PMC: 3777662. DOI: 10.4049/jimmunol.1301005. View

Vinuesa C, Cook M, Angelucci C, Athanasopoulos V, Rui L, Hill K . A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature. 2005; 435(7041):452-8. DOI: 10.1038/nature03555. View

Hedrich C, Crispin J, Tsokos G . Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity. 2014; 47(4):234-41. DOI: 10.3109/08916934.2013.801462. View

Krishnan S, Nambiar M, Warke V, Fisher C, Mitchell J, Delaney N . Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol. 2004; 172(12):7821-31. DOI: 10.4049/jimmunol.172.12.7821. View

10.

Kyttaris V, Zhang Z, Kampagianni O, Tsokos G . Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum. 2011; 63(7):2058-66. PMC: 3128171. DOI: 10.1002/art.30353. View

11.

Sunahori K, Nagpal K, Hedrich C, Mizui M, Fitzgerald L, Tsokos G . The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway.... J Biol Chem. 2013; 288(30):21936-44. PMC: 3724648. DOI: 10.1074/jbc.M113.467266. View

12.

Juang Y, Tenbrock K, Nambiar M, Gourley M, Tsokos G . Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol. 2002; 169(10):6048-55. DOI: 10.4049/jimmunol.169.10.6048. View

13.

Perl A . Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol. 2013; 9(11):674-86. PMC: 4046645. DOI: 10.1038/nrrheum.2013.147. View

14.

Ichinose K, Rauen T, Juang Y, Kis-Toth K, Mizui M, Koga T . Cutting edge: Calcium/Calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J Immunol. 2011; 187(11):5500-4. PMC: 3221799. DOI: 10.4049/jimmunol.1102357. View

15.

Lai Z, Hanczko R, Bonilla E, Caza T, Clair B, Bartos A . N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012; 64(9):2937-46. PMC: 3411859. DOI: 10.1002/art.34502. View

16.

Jeffries M, Sawalha A . Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int J Clin Rheumtol. 2011; 6(4):423-439. PMC: 3241218. DOI: 10.2217/ijr.11.32. View

17.

Shivakumar S, Tsokos G, Datta S . T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol. 1989; 143(1):103-12. View

18.

Kyttaris V, Wang Y, Juang Y, Weinstein A, Tsokos G . Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol. 2007; 178(3):1960-6. DOI: 10.4049/jimmunol.178.3.1960. View

19.

Barber D, Bartolome A, Hernandez C, Flores J, Redondo C, Fernandez-Arias C . PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med. 2005; 11(9):933-5. DOI: 10.1038/nm1291. View

20.

Ivanov I, McKenzie B, Zhou L, Tadokoro C, Lepelley A, Lafaille J . The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006; 126(6):1121-33. DOI: 10.1016/j.cell.2006.07.035. View